Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
February 29 2024 - 8:00AM
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage
biopharmaceutical company developing novel fatty acid synthase
(FASN) inhibitors designed to target dysfunctional metabolic and
fibrotic pathways, today announced that management will participate
in two upcoming investor conferences.
- A fireside chat at the TD Cowen 44th
Annual Health Care Conference in Boston at 2:10 p.m. ET / 11:10
a.m. PT on March 5, 2024; and
- A podium presentation at the Leerink
Partners Global Biopharma Conference 2024 in Miami at 8:00 a.m. ET
/ 5:00 a.m. PT on March 13, 2024.
Webcasts of each presentation will be available in the Investors
& Media section of Sagimet’s website at www.sagimet.com, with
archived replays available for 90 days following the live
event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing
novel fatty acid synthase (FASN) inhibitors that are designed to
target dysfunctional metabolic pathways in diseases resulting from
the overproduction of the fatty acid, palmitate. Sagimet’s lead
drug candidate, denifanstat, is an oral, once-daily pill and
selective FASN inhibitor in development for the treatment of NASH,
for which there are no treatments currently approved in the United
States or Europe. FASCINATE-2, a Phase 2b clinical trial of
denifanstat in NASH with liver biopsy-based primary endpoints, was
successfully completed with positive results.
Contact:
Maria YonkoskiICR
Westwicke203-682-7167maria.yonkoski@westwicke.com
Sagiment Biosciences (NASDAQ:SGMT)
Historical Stock Chart
From May 2024 to Jun 2024
Sagiment Biosciences (NASDAQ:SGMT)
Historical Stock Chart
From Jun 2023 to Jun 2024